AI Terminal
Apontis Pharma AG
M&A Activity • Jun 13, 2025
725_rns_2025-06-13_3bf095aa-1777-4b36-bbb8-e2390d9ae04b.html
M&A Activity
Open in ViewerOpens in native device viewer
News Details
Ad-hoc | 13 June 2025 10:30
APONTIS PHARMA AG: Merger Squeeze-out Cash Compensation Determined at EUR 10.40
APONTIS PHARMA AG / Key word(s): Squeeze Out
APONTIS PHARMA AG: Merger Squeeze-out Cash Compensation Determined at EUR 10.40
13-Jun-2025 / 10:30 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.
Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014
**APONTIS PHARMA AG: Merger Squeeze-out Cash Compensation Determined at EUR 10.40
Monheim / Rhein, 13 June 2025. APONTIS PHARMA AG announces that Zentiva AG submitted a specified request ( konkretisiertes Verlangen ) to the APONTIS PHARMA AG management board, pursuant to section 62 para. 1 and 5 first sentence of the German Transformation Act ( Umwandlungsgesetz – UmwG ) in conjunction with sections 327a et seqq. of the German Stock Corporation Act ( Aktiengesetz – AktG ), to convene the APONTIS PHARMA AG’s annual general meeting to resolve on the transfer of shares held by APONTIS PHARMA AG’s minority shareholders to Zentiva AG against adequate cash compensation.
Zentiva AG currently holds approximately 91.95% and, after deducting the number of treasury shares pursuant to section 62 para. 1 sentence 2 UmwG, approximately 93.83% of APONTIS PHARMA AG’s share capital and is therefore the major shareholder of APONTIS PHARMA AG as defined by section 62 para. 5 UmwG. Zentiva AG has determined the amount of the cash compensation to be EUR 10.40 per APONTIS PHARMA AG share. The court-appointed expert auditor has already indicated that, from a current standpoint, it will confirm the cash compensation to be adequate.
The conclusion and notarization of the merger agreement between APONTIS PHARMA AG and Zentiva AG will take place today. At APONTIS PHARMA AG’s annual general meeting, which is expected to be held on 29 July 2025, a resolution will be adopted on transferring APONTIS PHARMA AG minority shareholders’ shares to Zentiva AG against a cash compensation of EUR 10.40 per share.
The effectiveness of the merger squeeze-out is still subject to the approval by the APONTIS PHARMA AG annual general meeting and the registration of both the transfer resolution and the merger in the commercial register at the seat of APONTIS PHARMA AG, as well as the registration of the merger in the commercial register at the seat of Zentiva AG.
APONTIS PHARMA AG
Investor Relations
T: +49 2173 89 55 4900
F: +49 2173 89 55 1521
Alfred-Nobel-Str. 10
40789 Monheim / Rhein
Germany
APONTIS PHARMA press contact
CROSS ALLIANCE communication GmbH
Sven Pauly
T: +49 89 125 09 0330
End of Inside Information
13-Jun-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
| Language: | English |
| Company: | APONTIS PHARMA AG |
| Rolf-Schwarz-Schütte-Platz 1 | |
| 40789 Monheim am Rhein | |
| Germany | |
| E-mail: | [email protected] |
| Internet: | https://apontis-pharma.de/ |
| ISIN: | DE000A3CMGM5 |
| WKN: | A3CMGM |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2154370 |
| End of Announcement | EQS News Service |
2154370 13-Jun-2025 CET/CEST